Observational studyMedicine2025
Impact of dietary index for gut microbiota on muscle and bone health: A cross-sectional study.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of microbiome alterations on fracture healing and nonunion: a narrative review.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Distortions in homeostasis of the gut microbiota may be correlated with or may even contribute to abnormalities in musculoskeletal system function. This study thus aims to examine the impact of dietary index for gut microbiota (DI-GM) on bone and muscle health. This study utilized data extracted from the National Health and Nutrition Examination Survey database. Dietary data was used to calculate DI-GM. Osteoporosis, bone mineral density (BMD), sarcopenia, muscle quality index (MQI) and fracture were selected as observational indicators in this study. The random forest algorithm filled in the missing data. The weighted data were utilized to create logistic or linear regression models. Odds ratios (ORs) or beta, along with their corresponding 95% confidence intervals (CIs), were calculated. In addition, restricted cubic spline and stratification analysis were performed. DI-GM decreased the risk of osteoporosis (OR: 0.96; 95% CI: 0.93-0.996; P = .03). DI-GM decreased the likelihood of sarcopenia (OR: 0.86; 95% CI: 0.77-0.96; P = .01) and increased MQI (beta: 0.02; 95% CI: 0.01-0.03; P = .002) and BMD (beta: 0.003; 95% CI: 0.001-0.005; P = .001). However, no association was observed between DI-GM and sarcopenia, BMD, MQI after adjusting for covariates. Nevertheless, no correlation was observed between DI-GM and fracture. Additionally, a nonlinear relationship between DI-GM and osteoporosis was found after adjustment (P = .002), with an inflection point at 3.97 (median is 4), and risk dropped rapidly above this threshold. DI-GM decreases the risk of osteoporosis and sarcopenia and increases BMD and MQI, especially osteoporosis. However, it had no effect on fractures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.